De Vinci C, Levine P H, Pizza G, Fudenberg H H, Orens P, Pearson G, Viza D
Immunodiagnosis and Immunotherapy Unit, 1st Division of Urology Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Biotherapy. 1996;9(1-3):87-90. doi: 10.1007/BF02628663.
Transfer Factor (TF) was used in a placebo controlled pilot study of 20 patients with chronic fatigue syndrome (CFS). Efficacy of the treatment was evaluated by clinical monitoring and testing for antibodies to Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6). Of the 20 patients in the placebo-controlled trial, improvement was observed in 12 patients, generally within 3-6 weeks of beginning treatment. Herpes virus serology seldom correlated with clinical response. This study provided experience with oral TF, useful in designing a larger placebo-controlled clinical trial.
转移因子（TF）用于一项针对20例慢性疲劳综合征（CFS）患者的安慰剂对照试验性研究。通过临床监测以及检测针对EB病毒（EBV）和人疱疹病毒6型（HHV-6）的抗体来评估治疗效果。在该安慰剂对照试验的20例患者中，12例患者病情有改善，通常在开始治疗后的3至6周内。疱疹病毒血清学结果很少与临床反应相关。本研究提供了口服TF的经验，有助于设计规模更大的安慰剂对照临床试验。
